S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
Followed 114 Times  
NYSE:JNJ

Johnson & Johnson - JNJ Stock Forecast, Price & News

$163.40
+0.04 (+0.02%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$161.42
▼
$163.88
50-Day Range
$162.00
▼
$180.25
52-Week Range
$155.72
▼
$186.69
Volume
7.29 million shs
Average Volume
8.07 million shs
Market Capitalization
$427.21 billion
P/E Ratio
24.24
Dividend Yield
2.75%
Price Target
$185.23

Johnson & Johnson MarketRank™ Forecast

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
7.5% Upside
$175.71 Price Target
Short Interest
Healthy
0.32% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.23mentions of Johnson & Johnson in the last 14 days
Based on 43 Articles This Week
Insider Trading
Selling Shares
$34.93 M Sold Last Quarter
Proj. Earnings Growth
3.81%
From $10.51 to $10.91 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

29th out of 1,029 stocks

Pharmaceutical Preparations Industry

11th out of 504 stocks

See Top Rated MarketRank™ Stocks Here
JNJ stock logo

About Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.





Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

February 4, 2023 | marketbeat.com
MarketBeat Week in Review – 1/30 - 2/3 (JNJ)
The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shot
February 1, 2023 | marketbeat.com
How Do Lawsuits Affect Johnson & Johnson's Stock Price? (JNJ)
JNJ's stock price was hit hard on Monday following the court's ruling for billions of dollars worth of lawsuits - what does this mean for investors?
February 7, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
January 30, 2023 | dividendstocks.com
AbbVie Stock: Dividend King ABBV Overview (JNJ)
January 26, 2023 | marketbeat.com
Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
Johnson & Johnson and Abbott Laboratories are 2 dividend kings guiding for growth in 2023 and are on track to increase their yield yet again.
January 25, 2023 | marketbeat.com
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (JNJ)
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
January 24, 2023 | marketbeat.com
J&J tops 4Q earnings forecasts as profit, revenue slip
Johnson & Johnson beat earnings expectations in the final quarter of 2022 even as a strong dollar and sinking COVID-19 vaccine sales hurt revenue
January 21, 2023 | marketbeat.com
MarketBeat Week in Review – 1/16 - 1/20 (JNJ)
The shortened trading week looks to be ending on a sour note over growing recession fears. Here are some of the top stories from our MarketBeat contributors
February 7, 2023 | Wall Street Watch Dogs (Ad)
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
January 20, 2023 | marketbeat.com
J&J subsidiary to pay $9.75M to resolve kickback allegations
Federal prosecutors say a subsidiary of health care company Johnson & Johnson has agreed to pay nearly $10 million to settle allegations that it violated federal and state law by providing free products to a surgeon
January 18, 2023 | marketbeat.com
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
January 17, 2023 | marketbeat.com
3 Dividend Stocks For Passive Income (JNJ)
I'm aiming to grow my passive income this year through adding these safe value stocks to my portfolio that have strong dividend yields.
February 7, 2023 | forbes.com
Appeals Court Clears The Way For 38,000 Johnson & Johnson Baby Powder Lawsuits
February 7, 2023 | forbes.com
How Does Johnson & Johnson Stock Compare With This Large Beverage Company?
February 7, 2023 | finance.yahoo.com
The jig is up for the Texas two-step
February 6, 2023 | finance.yahoo.com
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
February 6, 2023 | finance.yahoo.com
Johnson & Johnson's Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
February 6, 2023 | msn.com
Johnson & Johnson's Latest Talcum Powder Development Could Be Costly
February 6, 2023 | seekingalpha.com
Johnson & Johnson succeeds in mid-stage trial for fetal disorder candidate
February 5, 2023 | fool.com
2 Reasons to Buy Johnson & Johnson, and 2 Reasons to Sell
February 3, 2023 | bizjournals.com
Johnson & Johnson unit plots job cuts; James Merson to depart
February 3, 2023 | finance.yahoo.com
Veterans Suing Over 3M Earplugs Want Bankruptcy Case Tossed
February 3, 2023 | finance.yahoo.com
13 Best Value Dividend Stocks to Buy
February 3, 2023 | benzinga.com
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
February 3, 2023 | finance.yahoo.com
3 Dow Stocks That Make for Screaming Buys in February
February 3, 2023 | americanbankingnews.com
Johnson & Johnson (NYSE:JNJ) Rating Reiterated by Cantor Fitzgerald
February 2, 2023 | wsj.com
Johnson & Johnson to Participate in the Cowen 43(rd) Annual HealthCare Conference
See More Headlines
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Company Calendar

Ex-Dividend for 12/6 Dividend
11/21/2022
Dividend Payable
12/06/2022
Last Earnings
1/24/2023
Today
2/07/2023
Ex-Dividend for 3/7 Dividend
2/17/2023
Dividend Payable
3/07/2023
Next Earnings (Estimated)
4/18/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:JNJ
CUSIP
47816010
CIK
200406
Web
www.jnj.com
Phone
(732) 524-0400
Fax
732-214-0332
Employees
141,700
Year Founded
1886

Price Target and Rating

Average Stock Price Forecast
$175.71
High Stock Price Forecast
$215.00
Low Stock Price Forecast
$52.00
Forecasted Upside/Downside
+13.4%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$6.74
Trailing P/E Ratio
24.24
Forward P/E Ratio
15.55
P/E Growth
2.83
Net Income
$17.94 billion
Net Margins
18.90%
Pretax Margin
22.88%
Return on Equity
35.94%
Return on Assets
15.27%

Debt

Debt-to-Equity Ratio
0.37
Current Ratio
1.43
Quick Ratio
1.18

Sales & Book Value

Annual Sales
$94.94 billion
Price / Sales
4.50
Cash Flow
$12.67 per share
Price / Cash Flow
12.90
Book Value
$28.12 per share
Price / Book
5.81

Miscellaneous

Outstanding Shares
2,614,480,000
Free Float
2,605,333,000
Market Cap
$427.21 billion
Optionable
Optionable
Beta
0.54

Social Links


Key Executives

  • Joaquin DuatoJoaquin Duato
    Chairman & Chief Executive Officer
  • Joseph J. WolkJoseph J. Wolk
    Chief Financial Officer & Executive Vice President
  • Matthew Stuckley
    Senior Finance Director
  • James D. Swanson
    Global Chief Information Officer & Executive VP
  • Ahmet Tezel
    Global Head-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













JNJ Stock - Frequently Asked Questions

Should I buy or sell Johnson & Johnson stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" JNJ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNJ, but not buy additional shares or sell existing shares.
View JNJ analyst ratings or view top-rated stocks.

What is Johnson & Johnson's stock price forecast for 2023?

13 Wall Street research analysts have issued twelve-month price objectives for Johnson & Johnson's stock. Their JNJ share price forecasts range from $52.00 to $215.00. On average, they anticipate the company's share price to reach $175.71 in the next year. This suggests a possible upside of 8.1% from the stock's current price.
View analysts price targets for JNJ or view top-rated stocks among Wall Street analysts.

How have JNJ shares performed in 2023?

Johnson & Johnson's stock was trading at $176.65 on January 1st, 2023. Since then, JNJ stock has decreased by 8.0% and is now trading at $162.53.
View the best growth stocks for 2023 here.

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a drop in short interest in the month of December. As of December 30th, there was short interest totaling 9,980,000 shares, a drop of 18.8% from the December 15th total of 12,290,000 shares. Based on an average daily volume of 6,510,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.4% of the shares of the company are short sold.
View Johnson & Johnson's Short Interest.

When is Johnson & Johnson's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 18th 2023.
View our JNJ earnings forecast.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday, January, 24th. The company reported $2.35 earnings per share for the quarter, beating analysts' consensus estimates of $2.22 by $0.13. The company earned $23.71 billion during the quarter, compared to analysts' expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a trailing twelve-month return on equity of 35.94%. Johnson & Johnson's revenue was down 4.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.13 EPS.
Read the conference call transcript.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Tuesday, January 3rd. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share on Tuesday, March 7th. This represents a $4.52 annualized dividend and a dividend yield of 2.78%. The ex-dividend date of this dividend is Friday, February 17th.
Read our dividend analysis for JNJ.

Is Johnson & Johnson a good dividend stock?

Johnson & Johnson (NYSE:JNJ) pays an annual dividend of $4.52 per share and currently has a dividend yield of 2.75%. The company has been increasing its dividend for 61 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 67.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, JNJ will have a dividend payout ratio of 41.43% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for JNJ.

How will Johnson & Johnson's stock buyback program work?

Johnson & Johnson declared that its Board of Directors has approved a share repurchase plan on Wednesday, September 14th 2022, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's leadership believes its stock is undervalued.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY23 earnings guidance on Tuesday, January, 24th. The company provided EPS guidance of $10.45-10.65 for the period, compared to the consensus estimate of $10.33. The company issued revenue guidance of $96.9-97.9 billion, compared to the consensus revenue estimate of $97.73 billion.

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?

2,535 employees have rated Johnson & Johnson Chief Executive Officer Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among the company's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), Procter & Gamble (PG) and AbbVie (ABBV).

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a variety of institutional and retail investors. Top institutional investors include Robert Wood Johnson Foundation (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.31%), Fisher Asset Management LLC (0.23%), Flossbach Von Storch AG (0.21%), New York State Common Retirement Fund (0.19%) and Ninety One UK Ltd (0.19%). Insiders that own company stock include Ashley Mcevoy, Jennifer L Taubert, Joseph J Wolk, Kathryn E Wengel, Michael E Sneed, Peter Fasolo, Robert J Decker, Thibaut Mongon, William D Perez and William Hait.
View institutional ownership trends.

How do I buy shares of Johnson & Johnson?

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $162.53.

How much money does Johnson & Johnson make?

Johnson & Johnson (NYSE:JNJ) has a market capitalization of $424.93 billion and generates $94.94 billion in revenue each year. The company earns $17.94 billion in net income (profit) each year or $6.74 on an earnings per share basis.

How many employees does Johnson & Johnson have?

The company employs 141,700 workers across the globe.

Does Johnson & Johnson have any subsidiaries?
The following companies are subsidiares of Johnson & Johnson: 3Dintegrated ApS, ALZA Corporation, AMO (Hangzhou) Co. Ltd., AMO (Shanghai) Medical Devices Trading Co. Ltd Beijing Branch, AMO (Shanghai) Medical Devices Trading Co. Ltd Guangzhou Branch, AMO (Shanghai) Medical Devices Trading Co. Ltd., AMO ASIA LIMITED, AMO Asia Limited (Korea Branch), AMO Asia Limited Taiwan Branch (Hong Kong), AMO Australia Pty Limited, AMO Australia Pty Limited (New Zealand Branch), AMO Canada Company, AMO Denmark ApS, AMO Development LLC, AMO France, AMO Germany GmbH, AMO Groningen B.V., AMO International Holdings Unlimited Company, AMO Ireland, AMO Ireland Ireland Branch, AMO Italy SRL, AMO Japan K.K., AMO Manufacturing USA LLC, AMO Netherlands BV, AMO Nominee Holdings LLC, AMO Norway AS, AMO Puerto Rico Manufacturing Inc., AMO Sales and Service Inc., AMO Singapore Pte. Ltd., AMO Spain Holdings LLC, AMO Switzerland GmbH, AMO U.K. Holdings LLC, AMO United Kingdom Ltd., AMO Uppsala AB, AUB Holdings LLC, Abott Medical Optics, Acclarent Inc., Actelion Ltd, Actelion Pharmaceuticals, Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd., Actelion Pharmaceuticals US Inc., Actelion Treasury Unlimited Company, Akros Medical Inc., Albany Street LLC, Alios BioPharma, Alza Land Management Inc., Anakuria Therapeutics Inc., Animas Diabetes Care LLC, Animas LLC, Animas Technologies LLC, AorTx Inc., Apsis, Aragon Pharmaceuticals, Aragon Pharmaceuticals Inc., Asia Pacific Holdings LLC, Atrionix Inc., Auris Health, Auris Health Inc., Backsvalan 2 Aktiebolag, Backsvalan 6 Handelsbolag, Beijing Dabao Cosmetics Co. Ltd., BeneVir BioPharm Inc., Berna Rhein B.V., BioMedical Enterprises Inc., Biosense Webster (Israel) Ltd., Biosense Webster Inc., Branch of Johnson & Johnson LLC (RU) in Kazakhstan, C Consumer Products Denmark ApS, CSATS Inc., Calibra Medical LLC, Campus-Foyer Apotheke GmbH, Carlo Erba OTC S.r.l., Centocor Biologics LLC, Centocor Research & Development Inc., Cerenovus Inc., ChromaGenics B.V., Ci:Labo Customer Marketing Co. Ltd., Ci:Labo USA Inc., Ci:z Holdings, Ci:z. Labo Co. Ltd., Cilag AG, Cilag GmbH International, Cilag Holding AG, Cilag Holding Treasury Unlimited Company, Cilag-Biotech S.L., CoTherix Inc., Coherex Medical Inc., ColBar LifeScience Ltd., Company Store.com Inc., Conor MedSystems, Cordis International Corporation, Cordis de Mexico S.A. de C.V., Corimmun GmbH, DePuy Hellas SA, DePuy International Limited, DePuy Ireland Unlimited Company, DePuy Mexico S.A. de C.V., DePuy Mitek LLC, DePuy Orthopaedics Inc., DePuy Products Inc., DePuy Spine LLC, DePuy Synthes Gorgan Limited, DePuy Synthes Inc., DePuy Synthes Institute LLC, DePuy Synthes Leto SARL, DePuy Synthes Products Inc., DePuy Synthes Sales Inc., Debs-Vogue Corporation (Proprietary) Limited, Dutch Holding LLC, ECL7 LLC, EES Holdings de Mexico S. de R.L. de C.V., EES S.A. de C.V., EIT Emerging Implant Technologies GmbH, Ethicon Endo-Surgery (Europe) GmbH, Ethicon Endo-Surgery Inc., Ethicon Endo-Surgery LLC, Ethicon Inc., Ethicon LLC, Ethicon PR Holdings Unlimited Company, Ethicon Sarl, Ethicon US LLC, Ethicon Women's Health & Urology Sarl, Ethnor (Proprietary) Limited, Ethnor Farmaceutica S.A., Ethnor del Istmo S.A., FMS Future Medical System SA, Finsbury (Development) Limited, Finsbury (Instruments) Limited, Finsbury Medical Limited, Finsbury Orthopaedics International Limited, Finsbury Orthopaedics Limited, GH Biotech Holdings Limited, GMED Healthcare BV, GMED Healthcare BV (Branch), Global Investment Participation B.V., Guangzhou Bioseal Biotech Co. Ltd., Hansen Medical Deutschland GmbH, Hansen Medical Inc., Hansen Medical International Inc., Hansen Medical UK Limited, Healthcare Services (Shanghai) Ltd., Hickory Merger Sub Inc., I.D. Acquisition Corp., Innomedic Gesellschaft für innovative Medizintechnik und Informatik mbH, Innovative Surgical Solutions LLC, J & J Company West Africa Limited, J&J Pension Trustees Limited, J-C Health Care Ltd., J.C. General Services BV, JJ Surgical Vision Spain S.L., JJC Acquisition Company B.V., JJHC LLC, JJSV Belgium BV, JJSV Manufacturing Malaysia SDN. BHD., JJSV Norden AB, JJSV Produtos Oticos Ltda., JNJ Global Business Services s.r.o., JNJ Holding EMEA B.V., JNJ International Investment LLC, JOM Pharmaceutical Services Inc., Janssen Alzheimer Immunotherapy (Holding) Limited, Janssen BioPharma LLC, Janssen Biologics (Ireland) Limited, Janssen Biologics B.V., Janssen Biotech Inc., Janssen Cilag C.A., Janssen Cilag Farmaceutica S.A., Janssen Cilag S.p.A., Janssen Cilag SPA, Janssen Development Finance Unlimited Company, Janssen Diagnostics LLC, Janssen Egypt LLC, Janssen Farmaceutica Portugal Lda, Janssen Global Services LLC, Janssen Holding GmbH, Janssen Inc., Janssen Irish Finance Unlimited Company, Janssen Korea Ltd., Janssen Oncology Inc., Janssen Ortho LLC, Janssen Pharmaceutica (Proprietary) Limited, Janssen Pharmaceutica NV, Janssen Pharmaceutica S.A., Janssen Pharmaceutical K.K., Janssen Pharmaceutical Sciences Unlimited Company, Janssen Pharmaceutical Unlimited Company, Janssen Pharmaceuticals Inc., Janssen Pharmaceuticals Inc. Japan Branch, Janssen Products LP, Janssen R&D Ireland Unlimited Company, Janssen Research & Development LLC, Janssen Sciences Ireland Unlimited Company, Janssen Scientific Affairs LLC, Janssen Supply Group LLC, Janssen Vaccines & Prevention B.V., Janssen Vaccines Branch of Cilag GmbH International, Janssen Vaccines Corp., Janssen-Cilag, Janssen-Cilag (New Zealand) Limited, Janssen-Cilag A/S, Janssen-Cilag AG, Janssen-Cilag AS, Janssen-Cilag Aktiebolag, Janssen-Cilag B.V., Janssen-Cilag Farmaceutica Lda., Janssen-Cilag Farmaceutica Ltda., Janssen-Cilag GmbH, Janssen-Cilag International NV, Janssen-Cilag Kft., Janssen-Cilag Kft. Branch Office, Janssen-Cilag Limited, Janssen-Cilag Manufacturing LLC, Janssen-Cilag NV, Janssen-Cilag OY, Janssen-Cilag Pharma GmbH, Janssen-Cilag Pharmaceutical S.A.C.I., Janssen-Cilag Polska Sp. z o.o., Janssen-Cilag Pty Ltd, Janssen-Cilag Pty Ltd (Branch), Janssen-Cilag S.A., Janssen-Cilag S.A., Janssen-Cilag S.A. de C.V., Janssen-Cilag de Mexico S. de R.L. de C.V., Janssen-Cilag s.r.o., Janssen-Pharma S.L., Jevco Holding Inc., Johnson & Johnson, Johnson & Johnson (Angola) Limitada, Johnson & Johnson (China) Investment Ltd., Johnson & Johnson (China) Investment Ltd. Beijing Branch, Johnson & Johnson (Egypt) S.A.E., Johnson & Johnson (Hong Kong) Limited, Johnson & Johnson (Ireland) Limited, Johnson & Johnson (Jamaica) Limited, Johnson & Johnson (Kenya) Limited, Johnson & Johnson (Middle East) Inc., Johnson & Johnson (Middle East) Inc. (DHCC Branch), Johnson & Johnson (Middle East) Inc. (JAFZA Branch), Johnson & Johnson (Middle East) Inc. Service Center (DAFZA Branch), Johnson & Johnson (Mozambique) Limitada, Johnson & Johnson (Namibia) (Proprietary) Limited, Johnson & Johnson (New Zealand) Limited, Johnson & Johnson (Philippines) Inc., Johnson & Johnson (Private) Limited, Johnson & Johnson (Thailand) Ltd., Johnson & Johnson (Trinidad) Limited, Johnson & Johnson (Vietnam) Co. Ltd, Johnson & Johnson - Societa' Per Azioni, Johnson & Johnson AB, Johnson & Johnson AB Eesti filiaal (Branch), Johnson & Johnson AG, Johnson & Johnson AG (Zuchwil Branch), Johnson & Johnson Belgium Finance Company BV, Johnson & Johnson Bulgaria EOOD, Johnson & Johnson China Ltd., Johnson & Johnson Consumer (Hong Kong) Limited, Johnson & Johnson Consumer (Thailand) Limited, Johnson & Johnson Consumer B.V., Johnson & Johnson Consumer Health Care Switzerland Branch of Janssen-Cilag AG, Johnson & Johnson Consumer Holdings France, Johnson & Johnson Consumer Inc., Johnson & Johnson Consumer Inc. (Dominican Republic Branch), Johnson & Johnson Consumer NV, Johnson & Johnson Consumer Saudi Arabia Limited, Johnson & Johnson Consumer Services EAME Ltd., Johnson & Johnson Del Paraguay S.A., Johnson & Johnson Dominicana S.A.S., Johnson & Johnson Enterprise Innovation Inc., Johnson & Johnson European Treasury Unlimited Company, Johnson & Johnson Finance Corporation, Johnson & Johnson Finance Limited, Johnson & Johnson Financial Services GmbH, Johnson & Johnson Financial Services GmbH (Branch Office), Johnson & Johnson Gateway LLC, Johnson & Johnson Gesellschaft m.b.H., Johnson & Johnson GmbH, Johnson & Johnson Guatemala S.A., Johnson & Johnson Health Care Systems Inc., Johnson & Johnson Health and Wellness Solutions Inc., Johnson & Johnson Hellas Commercial and Industrial S.A., Johnson & Johnson Hellas Consumer Products Commercial Societe Anonyme, Johnson & Johnson Hemisferica S.A., Johnson & Johnson Holding GmbH, Johnson & Johnson Inc., Johnson & Johnson Industrial Ltda., Johnson & Johnson Innovation - JJDC Inc., Johnson & Johnson Innovation LLC, Johnson & Johnson Innovation Limited, Johnson & Johnson International, Johnson & Johnson International (Belgian Branch) (European Logistics Center), Johnson & Johnson International (Singapore) Pte. Ltd., Johnson & Johnson International (Singapore) Pte. Ltd. (Branch), Johnson & Johnson International Financial Services Unlimited Company, Johnson & Johnson K.K., Johnson & Johnson Kft., Johnson & Johnson Korea Ltd., Johnson & Johnson Korea Selling & Distribution LLC, Johnson & Johnson LLC, Johnson & Johnson Lda, Johnson & Johnson Limited, Johnson & Johnson Limited (Sri Lanka Branch), Johnson & Johnson Luxembourg Finance Company Sarl, Johnson & Johnson Management Limited, Johnson & Johnson Medical (China) Ltd., Johnson & Johnson Medical (Proprietary) Ltd, Johnson & Johnson Medical (Shanghai) Ltd., Johnson & Johnson Medical (Shanghai) Ltd. Beijing Branch, Johnson & Johnson Medical (Suzhou) Ltd., Johnson & Johnson Medical B.V., Johnson & Johnson Medical Devices & Diagnostics Group - Latin America L.L.C., Johnson & Johnson Medical GmbH, Johnson & Johnson Medical Korea Ltd., Johnson & Johnson Medical Limited, Johnson & Johnson Medical Mexico S.A. de C.V., Johnson & Johnson Medical NV, Johnson & Johnson Medical Products GmbH, Johnson & Johnson Medical Pty Ltd, Johnson & Johnson Medical S.A., Johnson & Johnson Medical S.C.S., Johnson & Johnson Medical S.p.A., Johnson & Johnson Medical SAS, Johnson & Johnson Medical Saudi Arabia Limited, Johnson & Johnson Medical Taiwan Ltd., Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi, Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi (Ankara Branch), Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi (Izmir Branch), Johnson & Johnson Middle East - Scientific Office, Johnson & Johnson Middle East FZ - LLC (Lebanese Branch), Johnson & Johnson Middle East FZ-LLC, Johnson & Johnson Middle East FZ-LLC (Ghana Branch), Johnson & Johnson Middle East FZ-LLC (Kenya Branch), Johnson & Johnson Middle East FZ-LLC Branch (TSO) (Saudi Arabia Branch), Johnson & Johnson Morocco Societe Anonyme, Johnson & Johnson NCB (Belgian Branch), Johnson & Johnson Nordic AB, Johnson & Johnson Pacific Pty Limited, Johnson & Johnson Pakistan (Private) Limited, Johnson & Johnson Panama S.A., Johnson & Johnson Personal Care (Chile) S.A., Johnson & Johnson Poland Sp. z o.o., Johnson & Johnson Poland sp. z o.o. oddzial w Warszawie "Consumer", Johnson & Johnson Private Limited, Johnson & Johnson Pte. Ltd., Johnson & Johnson Pte. Ltd. Korea Branch, Johnson & Johnson Pty. Limited, Johnson & Johnson Romania S.R.L., Johnson & Johnson S.A., Johnson & Johnson S.A. de C.V., Johnson & Johnson S.E. Inc., Johnson & Johnson S.E. d.o.o., Johnson & Johnson SDN. BHD., Johnson & Johnson Sante Beaute France, Johnson & Johnson Services Inc., Johnson & Johnson Surgical Vision Inc., Johnson & Johnson Surgical Vision India Private Limited, Johnson & Johnson Taiwan Ltd., Johnson & Johnson UK Treasury Company Limited, Johnson & Johnson Ukraine LLC, Johnson & Johnson Urban Renewal Associates, Johnson & Johnson Vision Care (Shanghai) Ltd., Johnson & Johnson Vision Care Inc., Johnson & Johnson Vision Care Ireland Unlimited Company, Johnson & Johnson d.o.o., Johnson & Johnson de Argentina S.A.C. e. I., Johnson & Johnson de Chile Limitada, Johnson & Johnson de Chile S.A., Johnson & Johnson de Colombia S.A., Johnson & Johnson de Mexico S.A. de C.V., Johnson & Johnson de Uruguay S.A., Johnson & Johnson de Venezuela S.A., Johnson & Johnson del Ecuador S.A., Johnson & Johnson del Peru S.A., Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda., Johnson & Johnson for Export and Import LLC, Johnson & Johnson s.r.o., Johnson Y Johnson de Costa Rica S.A., Johnson and Johnson (Proprietary) Limited, Johnson and Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi, LTL Management LLC, La Concha Land Investment Corporation, Latam International Investment Company Unlimited Company, Legal Entity Name, MDS Co. Ltd., McNEIL MMP LLC, McNeil AB, McNeil Consumer Pharmaceuticals Co., McNeil Denmark ApS, McNeil Healthcare (Ireland) Limited, McNeil Healthcare (UK) Limited, McNeil Healthcare LLC, McNeil Iberica S.L.U., McNeil LA LLC, McNeil Nutritionals LLC, McNeil Panama LLC, McNeil Products Limited, McNeil Sweden AB, Medical Device Business Services Inc., Medical Devices & Diagnostics Global Services LLC, Medical Devices International LLC, Medos International Sarl, Medos International Sàrl succursale de Neuchâtel (Branch), Medos Sarl, MegaDyne Medical Products Inc., Menlo Care De Mexico S.A. de C.V., Mentor B.V., Mentor Deutschland GmbH, Mentor Medical Systems B.V., Mentor Partnership Holding Company I LLC, Mentor Texas GP LLC, Mentor Texas L.P., Mentor Worldwide LLC, Micrus Endovascular LLC, Middlesex Assurance Company Limited, Momenta Ireland Limited, Momenta Pharmaceuticals, Momenta Pharmaceuticals Inc., NeoStrata Company Inc., NeoStrata UG (haftungsbeschränkt), Netherlands Holding Company, NeuWave Medical Inc., Neuravi Limited, Novira Therapeutics, Novira Therapeutics LLC, NuVera Medical Inc., OBTECH Medical Sarl, OGX Beauty Limited, OMJ Holding GmbH, OMJ Ireland Unlimited Company, OMJ Pharmaceuticals Inc., Obtech Medical Mexico S.A. de C.V., Omrix Biopharmaceuticals Inc., Omrix Biopharmaceuticals Ltd., Omrix Biopharmaceuticals NV, Ortho Biologics LLC, Ortho Biotech Holding LLC, Ortho-McNeil Pharmaceutical LLC, Orthospin Ltd., Orthotaxy, PT Integrated Healthcare Indonesia, PT. Johnson & Johnson Indonesia, Patriot Pharmaceuticals LLC, Peninsula Pharmaceuticals LLC, Pharmadirect Ltd., Pharmedica Laboratories (Proprietary) Limited, Princeton Laboratories Inc., Productos de Cuidado Personal y de La Salud de Bolivia S.R.L., Proleader S.A., Pulsar Vascular Inc., Regency Urban Renewal Associates, RespiVert Ltd., RoC International, Royalty A&M LLC, Rutan Realty LLC, SYNTHES Medical Immobilien GmbH, Scios LLC, Sedona Singapore International Pte. Ltd., Sedona Thai International Co. Ltd., Serhum S.A. de C.V., Shanghai Elsker For Mother & Baby Co. Ltd, Shanghai Elsker Mother & Baby Co. Ltd Minghang Branch, Shanghai Johnson & Johnson Ltd., Shanghai Johnson & Johnson Pharmaceuticals Ltd., Sightbox LLC, Sodiac ESV, Spectrum Vision Limited Liability Company, Spectrum Vision Limited Liability Partnership, SterilMed, SterilMed Inc., Surgical Process Institute Deutschland GmbH, Synthes Costa Rica S.C.R. Limitada, Synthes GmbH, Synthes Holding AG, Synthes Holding Limited, Synthes Inc., Synthes Medical Surgical Equipment & Instruments Trading LLC, Synthes Produktions GmbH, Synthes Proprietary Limited, Synthes S.M.P. S. de R.L. de C.V., Synthes Tuttlingen GmbH, Synthes USA LLC, Synthes USA Products LLC, TARIS Biomedical, TARIS Biomedical LLC, TearScience Inc., The Anspach Effort LLC, The Vision Care Institute LLC, Tibotec LLC, Torax Medical Inc., UAB "Johnson & Johnson", UAB Johnson & Johnson Eesti Filiaal (Estonian Branch), Vania Expansion, Verb Surgical, Verb Surgical Inc., Vision Care Finance Unlimited Company, Vogue International, Vogue International LLC, Vogue International Trading Inc., WH4110 Development Company L.L.C., XO1, XO1 Limited, Xian Janssen Pharmaceutical Ltd., Xian-Janssen Pharmaceutical Ltd. Beijing Branch Office, Xian-Janssen Pharmaceutical Ltd. Shanghai Branch Office, Zarbee's Inc., and Zarbee's Naturals.
Read More
How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The official website for the company is www.jnj.com. The company can be reached via phone at (732) 524-0400 or via fax at 732-214-0332.

This page (NYSE:JNJ) was last updated on 2/7/2023 by MarketBeat.com Staff